The TRPV4 inhibitor HC‐067047 or hippocampal Trpv4 knockdown alleviates depression‐like behaviors by reducing astrocyte and microglia activation, with suppressed CaMKII‐NLRP3 inflammasome expression and serum IL‐6, TNF‐α, and IL‐1β levels, and increased neurogenesis in the hippocampus [146]. The gene discussed is TRPV4; the disease is depressive disorder.